> Details
Wölber, Linn
[Author];
Hampl, Monika
[Author];
Eulenburg, Christine Helene Gräfin zu
[Author];
Prieske, Katharina
[Author];
Hambrecht, Johanna
[Author];
Fürst, Sophie-Theresa
[Author];
Klapdor, Rüdiger
[Author];
Heublein, Sabine
[Author];
Gass, Paul
[Author];
Rohner, Annika
[Author];
Canzler, Ulrich
[Author];
Becker, Sven
[Author];
Bommert, Mareike Anna Katharina
[Author];
Bauerschlag, Dirk Olaf
[Author];
Denecke, Agnieszka
[Author];
Hanker, Lars
[Author];
Runnebaum, Ingo B.
[Author];
Forner, Dirk Michael
[Author];
Schochter, Fabienne
[Author];
Klar, Maximilian
[Author];
Schwab, Roxana Michaela
[Author];
Köpke, Melitta
[Author];
Kalder, Matthias
[Author];
Hantschmann, Peer
[Author];
[...]
Risk for pelvic metastasis and role of pelvic lymphadenectomy in node-positive vulvar cancer
: results from the AGO-VOP.2 QS vulva study
Sharing
Reference
management
Direct link
Bookmarks
Remove from
bookmarks
Share this by email
Share this on Twitter
Share this on Facebook
Share this on Whatsapp
- Media type: E-Article
- Title: Risk for pelvic metastasis and role of pelvic lymphadenectomy in node-positive vulvar cancer : results from the AGO-VOP.2 QS vulva study
- Contributor: Wölber, Linn [VerfasserIn]; Hampl, Monika [VerfasserIn]; Eulenburg, Christine Helene Gräfin zu [VerfasserIn]; Prieske, Katharina [VerfasserIn]; Hambrecht, Johanna [VerfasserIn]; Fürst, Sophie-Theresa [VerfasserIn]; Klapdor, Rüdiger [VerfasserIn]; Heublein, Sabine [VerfasserIn]; Gass, Paul [VerfasserIn]; Rohner, Annika [VerfasserIn]; Canzler, Ulrich [VerfasserIn]; Becker, Sven [VerfasserIn]; Bommert, Mareike Anna Katharina [VerfasserIn]; Bauerschlag, Dirk Olaf [VerfasserIn]; Denecke, Agnieszka [VerfasserIn]; Hanker, Lars [VerfasserIn]; Runnebaum, Ingo B. [VerfasserIn]; Forner, Dirk Michael [VerfasserIn]; Schochter, Fabienne [VerfasserIn]; Klar, Maximilian [VerfasserIn]; Schwab, Roxana Michaela [VerfasserIn]; Köpke, Melitta [VerfasserIn]; Kalder, Matthias [VerfasserIn]; Hantschmann, Peer [VerfasserIn]; Ratiu, Dominik Alexander [VerfasserIn]; Denschlag, Dominik [VerfasserIn]; Schroeder, Willibald [VerfasserIn]; Tuschy, Benjamin [VerfasserIn]; Baumann, Klaus [VerfasserIn]; Mustea, Alexander [VerfasserIn]; Soergel, Philipp [VerfasserIn]; Bronger, Holger [VerfasserIn]; Bauerschmitz, Gerd Johannes [VerfasserIn]; Kosse, Jens Fabian [VerfasserIn]; Koch, Martin C. [VerfasserIn]; Ignatov, Atanas [VerfasserIn]; Sehouli, Jalid [VerfasserIn]; Dannecker, Christian [VerfasserIn]; Mahner, Sven [VerfasserIn]; Jaeger, Anna [VerfasserIn]
- imprint: 14 January 2022
- Published in: Cancers ; 14(2022), 2, Artikel-ID 418, Seite 1-14
- Language: English
- DOI: 10.3390/cancers14020418
- ISSN: 2072-6694
- Identifier:
- Keywords: groin ; pelvic lymphadenectomy ; prognosis ; radiotherapy ; recurrence ; vulvar cancer
- Origination:
- Footnote:
- Description: The need for pelvic treatment in patients with node-positive vulvar cancer (VSCC) and the value of pelvic lymphadenectomy (LAE) as a staging procedure to plan adjuvant radiotherapy (RT) is controversial. In this retrospective, multicenter analysis, 306 patients with primary node-positive VSCC treated at 33 gynecologic oncology centers in Germany between 2017 and 2019 were analyzed. All patients received surgical staging of the groins; nodal status was as follows: 23.9% (73/306) pN1a, 23.5% (72/306) pN1b, 20.4% (62/306) pN2a/b, and 31.9% (97/306) pN2c/pN3. A total of 35.6% (109/306) received pelvic LAE; pelvic nodal involvement was observed in 18.5%. None of the patients with nodal status pN1a or pN1b and pelvic LAE showed pelvic nodal involvement. Taking only patients with nodal status ≥pN2a into account, the rate of pelvic involvement was 25%. In total, adjuvant RT was applied in 64.4% (197/306). Only half of the pelvic node-positive (N+) patients received adjuvant RT to the pelvis (50%, 10/20 patients); 41.9% (122/291 patients) experienced recurrent disease or died. In patients with histologically-confirmed pelvic metastases after LAE, distant recurrences were most frequently observed (7/20 recurrences). Conclusions: A relevant risk regarding pelvic nodal involvement was observed from nodal status pN2a and higher. Our data support the omission of pelvic treatment in patients with nodal status pN1a and pN1b.
- Access State: Open Access